Clinical Trials Directory

Trials / Completed

CompletedNCT02942888

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

The Effects of NAD on Brain Function and Cognition

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
46 (actual)
Sponsor
The University of Texas Health Science Center at San Antonio · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).

Detailed description

Niagen is a patented formula which is the first and only commercially available form of Nicotinamide Riboside (NR). It has been proven in basic science studies as a highly effective NAD booster, but it also works as a vitamin B3 supplement. NAD helps pass energy from glucose to other pathways in the cell. Niagen (Nicotinamide Riboside, vitamin B3) is one of the most effective NAD+ precursors to support cellular health. The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTNicotinamide ribosideOral administration of Niagen ramp up 250mg to 1g/day as tolerated
DIETARY_SUPPLEMENTSugar PillThis is a placebo compounded by ChromaDex, Inc.

Timeline

Start date
2017-11-30
Primary completion
2019-08-31
Completion
2021-08-16
First posted
2016-10-24
Last updated
2021-09-02

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02942888. Inclusion in this directory is not an endorsement.